fat loss
Quality Rating
Buy Cagrilintide 10mg
Long-acting amylin analogue — appetite suppression and fat loss via central satiety signaling
Amylin pathway satiety22.7% weight loss in CagriSema trialsAdditive to GLP-1s
Who This Is For
Users who have plateaued on GLP-1 agonists and want to add amylin-pathway appetite suppression, or those seeking the most potent appetite-based fat loss combination available.
Overview & Benefits
Cagrilintide is Novo Nordisk's long-acting amylin analogue, currently in Phase 3 trials as part of CagriSema (combined with semaglutide). Amylin is a pancreatic hormone that complements insulin by slowing gastric emptying, reducing glucagon secretion, and signaling satiety through the area postrema in the brainstem — a different pathway than GLP-1 receptor activation.
The clinical significance is that Cagrilintide and semaglutide act via additive mechanisms. CagriSema Phase 3 data showed 22.7% mean weight loss at 68 weeks — substantially more than either agent alone. Used independently, Cagrilintide delivers meaningful appetite suppression and body weight reduction via the amylin pathway, making it a logical complement to GLP-1 therapy or a standalone fat loss agent for those who have plateaued on semaglutide.
Key Benefits
- Amylin pathway satiety — complementary and additive to GLP-1 receptor agonism
- CagriSema combination shows 22.7% weight loss — more than either agent alone
- Slows gastric emptying and reduces glucagon secretion
- Long-acting once-weekly injection format
- Meaningful fat loss independent of GLP-1 mechanism
Protocols & Dosing
Once-Weekly Protocol
Once weeklyStart 0.3mg/week, titrate to 2.4mg/week over 16 weeks
Titrate slowly to minimize GI side effects. Can be combined with semaglutide for the CagriSema effect documented in clinical trials.
Buy Cagrilintide 10mg
$169.99
Buy Now — $169.99Buy at PhiogenResearch-grade · COA verified · Phiogen
Categoryfat loss
Typeinjectable
Quality Rating★★★★☆
VendorPhiogen
Cagrilintide 10mg
$169.99